Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.

Creator(s)

Keith J. August, Children's Mercy HospitalFollow
Sana Farooki, Children's Mercy Hospital
Joy M. Fulbright, Children's Mercy HospitalFollow
Amanda August, Children's Mercy HospitalFollow
Jay M. Portnoy, Children's Mercy HospitalFollow
Lauren Pommert
Michael J. Burke
Erin M. Guest, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

1-2020

Identifier

DOI: 10.1002/pbc.28021

Abstract

Hypersensitivity to pegaspargase is associated with inferior survival in pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. In the past year, drug-supply shortages have led to the lack of an available alternative to pegaspargase. Rather than omit asparaginase from the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma patients with hypersensitivity to pegaspargase, we continued pegaspargase treatments for nine pediatric patients, utilizing a rapid desensitization protocol. There were no adverse events related to the pegaspargase during desensitization, and all patients who were checked had asparaginase serum levels above the threshold of 0.1 IU/mL at 7 to 14 days after pegaspargase therapy.

Journal Title

Pediatric blood & cancer

Volume

67

Issue

1

MeSH Keywords

Adolescent; Antineoplastic Agents; Asparaginase; Desensitization, Immunologic; Humans; Lymphoma, T-Cell; Male; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis

Keywords

acute lymphoblastic leukemia; asparaginase; children; lymphoblastic lymphoma

Recommended Citation

August KJ, Farooki S, Fulbright JM, et al. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatr Blood Cancer. 2020;67(1):e28021. doi:10.1002/pbc.28021